Orviglance FDA submission during the summer Good cost control Conf call at 10:00 CEST
ANNONS
Recent relevant events
In mid'March '25, Ascelia communicated a positive outcome of the pre-NDA meeting with the FDA. In mid'April, Ascelia finished the warrants TO 1 capital raise, raising gross proceeds of SEK 43m. On 7 May, Ascelia held its AGM in Malmö, adopting all resolutions on the agenda. All board members including the chairman of the board were re-elected. Earlier this week, Ascelia's CEO Magnus Corfitzen held a presentation at the ABG Investor days and Ascelia clinical collaborators presented SPARKLE data at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting.
